Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial

MT Newswires Live

Oct 24, 2024

Gan & Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.

The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.

The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.

Shares of the company rose more than 2% in recent trade.

Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2477758528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477758528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477758528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-24 12:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477758528","market":"us","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.</p><p>The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.</p><p>The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.</p><p>Shares of the company rose more than 2% in recent trade.</p><p>Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-24 12:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Gan &amp; Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.</p><p>The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.</p><p>The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.</p><p>Shares of the company rose more than 2% in recent trade.</p><p>Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477758528","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477758528","pubTimestamp":1729745443,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gan & Lee Pharmaceuticals  dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.Shares of the company rose more than 2% in recent trade.Price : 52.15, Change: +1.3, Percent Change: +2.48%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"甘李药业银屑病药物试验首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":0.9},"content_text":"Gan & Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.Shares of the company rose more than 2% in recent trade.Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}